生长激素分泌促进剂及构效关系研究进展

生长激素分泌促进剂是一类作用于垂体和下丘脑的具有专一性促生长激素释放作用的寡肽及其类似物.由于其分子质量小、活性高、可口服、作用专一而有可能成为新的生长激素治疗药物.目前已经发展了很多具有此类活性的多种结构的化合物,如肽、环肽、肽醇及非肽类似物等.尽管这类化合物的作用机制尚未完全明确,但已有证据表明存在新的调节生长激素分泌的途径和新的调节因子.     

不同的下丘脑肽和神经递质对鲤鱼促性腺激素和生长激素分泌活动的影响

以１龄性腺发育中期鲤鱼为材料,采用腹腔（ｉ．ｐ）注射的方法,研究不同的下丘脑肽和神经递质对鲤鱼促性腺激素（ＧｔＨ）和生长激素（ＧＨ）分泌的影响。结果表明：促甲状腺激素释放激素（ＴＲＨ）、Ｌ－多巴（Ｌ－ＤＯＰＡ）、甲基睾酮（ＭＴ）、γ－氨基丁酸（ＧＡＢＡ）、促黄体素释放激素类似物（ＬＨＲＨ－Ａ）和三碘甲状腺原氨酸（Ｔ３）都能显著刺激ＧｔＨ的分泌,但最大效应时间各不相同。ＴＲＨ和ＬＨＲＨ－Ａ能促进ＧＨ的分泌,Ｌ－ＤＯＰＡ、ＭＴ、ＧＡＢＡ对血清ＧＨ水平没有明显影响;Ｔ３则对ＧＨ分泌有一定的抑制作用。这说明鲤鱼ＧｔＨ和ＧＨ的分泌除了受各自的下丘脑释放因子和释放抑制因子的双重神经内分泌调控外,还受多种其它相同和不同调节因子的影响,也反映了鲤鱼ＧｔＨ和ＧＨ分泌的神经内分泌调控的复杂性。     

尼罗罗非鱼ghrelin基因的多态性及其与生长性状相关SNP位点的筛选

为了研究尼罗罗非鱼(Oreochromis niloticus)生长激素促分泌素基因(ghrelin)的多态性及其与生长的相关性, 研究以两个尼罗罗非鱼群体(快长群体和基础群体)的DNA样本各40份为模板, 通过PCR扩增和测序获得ghrelin基因序列。通过Dnasp v5和MEGA 5.0分析序列多态性、筛选有效SNP 位点; 采用Snapshot法对两个群体子代ghrelin基因中SNP位点进行基因分型, 然后分析SNP位点基因型与生长性状的相关性。结果表明, 快长群体ghrelin基因中的单核苷酸变异位点数(S)比基础群体要少, 而核苷酸多态性(Pi)和平均核苷酸差异数(K)要略高于基础群体。共筛得3个有效SNP 位点(S1、S2和S3), 均分布于第1个内含子中。遗传结构分析表明, 3个SNP 位点在两个群体的子代中均为低度多态性位点(PIC0.25), 但处于Hardy-Weinberg平衡(P0.05);快长群体子代中3个SNP 位点的观测杂合度、期望杂合度和多态信息含量等遗传多样性参数均小于基础群体子代的相应值, 3个SNP 位点的遗传多样性参数、基因型和基因频率在同一群体中高度一致, SNP 位点之间完全连锁。两个群体子代中3个SNP 位点处的优势基因型相同, 但快长群体子代中优势基因型频率要明显大于基础群体子代中相应基因型频率。对两个群体子代的生长性状与SNP基因型进行关联性分析的结果表明,尼罗罗非鱼个体的多项生长指标(体重、体长、体高、头长和尾柄高等)在不同基因型中存在显著差异(S1:GG AG, S2:TT AT, S3:AA AT)(P0.05)。D1双倍型(S1:GG, S2:TT, S3:AA)所对应的尼罗罗非鱼个体的多项生长指标(体重、体长、体高、头长和尾柄高等)显著高于D2双倍型(S1:AG, S2:AT, S3:AT)。以上结果表明, 尼罗罗非鱼ghrelin基因3个SNP 位点完全连锁, D1双倍型与快长性状密切相关, 可作为尼罗罗非鱼分子标记辅助育种的候选标记。     

不同的下丘脑肽和神经递质对鲤鱼促性腺激素和生物激素分泌活动的影响

以１龄性腺发育中期鲤鱼为材料,采用腹腔注射的方法,研究了不同的下丘脑肽和神经递质对鲤鱼促性腺激素和生长激素分泌的影响。结果表明：促甲状腺激素释放激素,Ｌ－多巴,甲基睾酮,γ－氨基丁酸,促黄体素主激素类似物和三磺甲状腺原氨酸者都能显著刺激ＧｔＨ的分泌,但最大效应时间各不相同。     

促性腺激素释放激素及多巴胺对斜带石斑鱼生长激素分泌及其mRNA表达的调控

研究斜带石斑鱼生长激素分泌及其mRNA表达的调控规律对于性别分化的控制、临床药物的选择,以及石斑鱼的增养殖等均具有重要的理论意义和实践意义。本文应用静态孵育系统,采用放射免疫测定法和化学发光液相杂交实验,研究GnRH和DA对斜带石斑鱼GH分泌、GHmRNA合成的调控作用。100nmol／LsGnRH作用斜带石斑鱼脑垂体碎片1也4h,明显促进GH的释放和GHmRNA的合成,并具有时间依存性;10nmol／L～1μmol／LsGnRH作用1h能明显促进斜带石斑鱼脑垂体释放GH,促进GHmRNA的合成,表现出明显的剂量效应。100nmol／L、1μmol／LmGnRH作用1h以一定的剂量依存方式促进GH的释放、促进GHmRNA的合成,但mGnRH的效应比相应剂量的sGnRH的作用弱。APO为DA受体的非选择性激动剂,不同剂量APO对斜带石斑鱼脑垂体碎片的作用结果显示,10nmol／L-1μmol／L APO以剂量依存方式促进斜带石斑鱼脑垂体碎片释放GH、促进GHmRNA的合成：1μmol／LAPO作用12h以上明显促进GH的释放和GHmRNA的合成,并随时间的延长而增加。与sGnRH对斜带石斑鱼GH释放、GHmRNA合成的作用相比,APO的作用较弱。本文研究结果证实GnRH和DA能促进斜带石斑鱼脑垂体GH释放和GHmRNA合成。     

妊娠期的促肾上腺皮质激素释放激素

妊娠中、晚期,胎盘分泌大量促肾上腺皮质激素释放激素（ＣＲＨ）进入母体和胎儿循环。胎盘分泌的ＣＲＨ除参与胎盘、垂体ＰＯＭＣ肽类释放外,还与异常妊娠有关。调节胎盘ＣＲＨ分泌的因子与下丘脑各有异同,糖皮质激素对胎盘ＣＲＨ分泌起正反馈作用,一氧化氮也对胎盘ＣＲＨ分泌具有抑制作用。     

长臀鮠生长激素的生殖周期变化

国内外学者对硬骨鱼类的GH的季节变动及神经内分泌调控有一定的研究 ,其中在鲤科和鲑鳟鱼类研究的较为深入 ,近来一些学者对鲇形目的胡子鲇科、科[1] 和鲇科[2 ] 做了一定的研究 ,研究结果表明 ,GH分泌和神经内分泌调节机理与鲤科鱼类在某些方面存在一定差异。如鲤科鱼类中 ,GnRH起着GH释放因子的作用 ,但非洲鲇鱼和鲇鱼[3 ] 中却未证实GnRH刺激GH释放 ,并且鲇鱼中GH分泌的季节变化与生殖之间有密切联系。鲇形目 (Siluriformes)鱼类在世界养殖鱼类中占有重要的位置。长臀 (CranoglanisbouderiusRichardson)是鲇形目中我国特有的…     

人生长激素研究进展

综述了人生长激素的结构,及最近几年国内外对人生长激素在分子结构、基因改造、制备、提纯及检测等方面的最新进展和研究趋势,对各种可能影响生长激素分泌的因素进行了分析、讨论。     

促甲状腺激素释放激素受体mRNA在大鼠睾丸中的表达(英文)

本应用原位杂交技术在大鼠睾丸恒冷箱切片上研究了促甲状腺激素释放激素受体（TRH－R）RNA的表达和定位。由DNA合成仪合成两个含48个碱基的寡核苷酸探针,两个探针分别与小鼠垂体TRH－R1005－1052和1332－1379区段的cDNA互补,生物素在5′末端标记寡核苷酸探针。结果显示TRH－R寡核苷酸探针与其互补的mRNA杂交信号集中在大鼠睾丸的间质细胞中,生精细胞地交信号,杂交信号的强度依探针浓度而增加,该结果表明RTH可能通过自分泌调节生殖功能和发育,TRH－R作用途径可能与在垂体的作用类似。     

乌脑龟垂体显微及其腺垂体超微结构的研究

乌龟脑垂体由柄形神经垂体和椭圆形腺垂体两部分组成,神经垂体位于腺垂体后部上方呈背腹型排列。神经垂体中神经叶不发达,腺垂体分为远侧部和中间部,特殊空泡结构成为垂体门脉系统的特征。远侧部细胞分为嗜酸性细胞、嗜碱性细胞和嫌色细胞3种。通过透射电镜观察,腺垂体远侧部主要有5种分泌激素细胞：即生长激素（GH）分泌细胞、催乳激素（PRL）分泌细胞、促甲状腺激素（TSH）分泌细胞、促肾上腺皮质激素（ACTH）分泌细胞、促性腺激素（GTH）分泌细胞和非分泌类型滤泡．星形细胞（Fs）。生长激素分泌细胞核大、分泌颗粒少的特征成为乌龟与其他动物最大的区别,可能与乌龟具有生长慢、寿命长的生物学特性有关。     

(D)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: synthesis and incorporation into the growth hormone secretagogues

The first enantioselective synthesis of (d)-2-tert-butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid 3 was achieved. The incorporation of the titled compound into growth hormone secretagogue (GHS) compounds resulted in new analogs 10 and 16, both of which had significantly increased in vitro potency. The compound 10 also showed improved in vivo efficacy as well as pharmacokinetic properties in rat models.     

Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion

Ghrelin is a native ligand for the growth hormone secretagogue (GHS) receptor that stimulates pulsatile GH secretion markedly. At present, no formal construct exists to unify ensemble effects of ghrelin, GH-releasing hormone (GHRH), somatostatin (SRIF), and GH feedback. To model such interactions, we have assumed that ghrelin can stimulate pituitary GH secretion directly, antagonize inhibition of pituitary GH release by SRIF, oppose suppression of GHRH neurons in the arcuate nucleus (ArC) by SRIF, and induce GHRH secretion from ArC. The dynamics of such connectivity yield self-renewable GH pulse patterns mirroring those in the adult male and female rat and explicate the following key experimental observations. 1) Constant GHS infusion stimulates pulsatile GH secretion. 2) GHS and GHRH display synergy in vivo. 3) A systemic pulse of GHS stimulates GH secretion in the female rat at any time and in the male more during a spontaneous peak than during a trough. 4) Transgenetic silencing of the neuronal GHS receptor blunts GH pulses in the female. 5) Intracerebroventricular administration of GHS induces GH secretion. The minimal construct of GHS-GHRH-SRIF-GH interactions should aid in integrating physiological data, testing regulatory hypotheses, and forecasting innovative experiments.     

Diversification and coevolution of the ghrelin/growth hormone secretagogue receptor system in vertebrates

The gut hormone ghrelin is involved in numerous metabolic functions, such as the stimulation of growth hormone secretion, gastric motility, and food intake. Ghrelin is modified by ghrelin O‐acyltransferase (GOAT) or membrane‐bound O‐acyltransferase domain‐containing 4 (MBOAT4) enabling action through the growth hormone secretagogue receptors (GHS‐R). During the course of evolution, initially strong ligand/receptor specificities can be disrupted by genomic changes, potentially modifying physiological roles of the ligand/receptor system. Here, we investigated the coevolution of ghrelin, GOAT, and GHS‐R in vertebrates. We combined similarity search, conserved synteny analyses, phylogenetic reconstructions, and protein structure comparisons to reconstruct the evolutionary history of the ghrelin system. Ghrelin remained a single‐gene locus in all vertebrate species, and accordingly, a single GHS‐R isoform was identified in all tetrapods. Similar patterns of the nonsynonymous (dN) and synonymous (dS) ratio (dN/dS) in the vertebrate lineage strongly suggest coevolution of the ghrelin and GHS‐R genes, supporting specific functional interactions and common physiological pathways. The selection profiles do not allow confirmation as to whether ghrelin binds specifically to GOAT, but the ghrelin dN/dS patterns are more similar to those of GOAT compared to MBOAT1 and MBOAT2 isoforms. Four GHS‐R isoforms were identified in teleost genomes. This diversification of GHS‐R resulted from successive rounds of duplications, some of which remained specific to the teleost lineage. Coevolution signals are lost in teleosts, presumably due to the diversification of GHS‐R but not the ghrelin gene. The identification of the GHS‐R diversity in teleosts provides a molecular basis for comparative studies on ghrelin's physiological roles and regulation, while the comparative sequence and structure analyses will assist translational medicine to determine structure–function relationships of the ghrelin/GHS‐R system.     

Model-projected mechanistic bases for sex differences in growth hormone regulation in humans

Models of physiological systems facilitate rational experimental design, inference, and prediction. A recent construct of regulated growth hormone (GH) secretion interlinks the actions of GH-releasing hormone (GHRH), somatostatin (SRIF), and GH secretagogues (GHS) with GH feedback in the rat (Farhy LS, Veldhuis JD. Am J Physiol Regul Integr Comp Physiol 288: R1649-R1663, 2005). In contrast, no comparable formalism exists to explicate GH dynamics in any other species. The present analyses explore whether a unifying model structure can represent species- and sex-defined distinctions in the human and rodent. The consensus principle that GHRH and GHS synergize in vivo but not in vitro was explicable by assuming that GHS 1) evokes GHRH release from the brain, 2) opposes inhibition by SRIF both in the hypothalamus and on the pituitary gland, and 3) stimulates pituitary GH release directly and additively with GHRH. The gender-selective principle that GH pulses are larger and more irregular in women than men was conferrable by way of 4) higher GHRH potency and 5) greater GHS efficacy. The overall construct predicts GHRH/GHS synergy in the human only in the presence of SRIF when the brain-pituitary nexus is intact, larger and more irregular GH pulses in women, and observed gender differences in feedback by GH and the single and paired actions of GHRH, GHS, and SRIF. The proposed model platform should enhance the framing and interpretation of novel clinical hypotheses and create a basis for interspecies generalization of GH-axis regulation.     

New growth hormone secretagogues

Starting from EP 51389, a potent growth hormone secretagogue(GHS), a new series of GHS has been designed, synthesized andtested. This series was built on a gem-diamino moiety and astructure activity relationship study was performed includingN-methylation of the amide bonds. Some analogues exhibited morepowerful activity than Hexarelin, they were active peros on dog and have been selected as candidates for furtherdevelopment.     

Endocrine and non-endocrine activities of growth hormone secretagogues in humans

Growth hormone (GH) secretagogues (GHS) are synthetic peptidyl and non-peptidyl molecules which possess strong, dose-dependent and reproducible GH releasing effects as well as significant prolactin (PRL) and adrenocorticotropic hormone (ACTH) releasing effects. The neuroendocrine activities of GHS are mediated by specific receptors mainly present at the pituitary and hypothalamic level but also elsewhere in the central nervous system. GHS release GH via actions at the pituitary and (mainly) the hypothalamic level, probably acting on GH releasing hormone (GHRH) secreting neurons and/or as functional somatostatin antagonists. GHS release more GH than GHRH and the coadministration of these peptides has a synergistic effect but these effects need the integrity of the hypothalamo-pituitary unit. The GH releasing effect of GHS is generally gender-independent and undergoes marked age-related variations reflecting age-related changes in the neural control of anterior pituitary function. The PRL releasing activity of GHS probably comes from direct pituitary action, which indeed is slight and independent of both age and gender. The acute stimulatory effect of GHS on ACTH/cortisol secretion is similar to that of corticotropin releasing hormone (CRH) and arginine vasopressin (AVP). In physiological conditions, the ACTH releasing activity of GHS is mediated by central mechanisms, at least partially, independent of both CRH and AVP but probably involving GABAergic mechanisms. The ACTH releasing activity of GHS is gender-independent and undergoes peculiar age-related variations showing a trend towards increase in ageing. GHS possess specific receptors also at the peripheral levels in endocrine and non-endocrine human tissues. Cardiac receptors are specific for peptidyl GHS and probably mediate GH-independent cardiotropic activities both in animals and in humans.     

New growth hormone secretagogues

Summary Starting from EP 51389, a potent growth hormone secretagogue (GHS), a new series of GHS has been designed, synthesized and tested. This series was built on a gem-diamino moiety and a structure activity relationship study was performed including N-methylation of the amide bonds. Some analogues exhibited more powerful activity than Hexarelin, they were activeper os on dog and have been selected as candidates for further development.     

Anatomy of the Hypophysiotropic Somatostatinergic and Growth Hormone-releasing Hormone System Minireview

The central control of growth hormone (GH) secretion from the pituitary gland is ultimately achieved by the interaction between two hypothalamic neurohormones, somatostatin which inhibits and growth hormone-releasing hormone (GHRH) which stimulates GH release. The regulation of the somatostatin and GHRH release from the hypothalamus is regulated by a range of other neuropeptides, neurotransmitters, neurohormones. In this mini review we attempt to provide a short summary covering the anatomy and chemical characteristics of the various cell populations regulating GH secretion as a tribute to Miklós Palkovits who pioneered the field of functional neuroanatomy of hypothalamic networks.Special Issue Dedicated to Miklós Palkovits.     

Ghrelin – Defender of fat

With one quarter of the population of the Western world now considered obese, it is essential that we understand the factors giving rise to elevated fat deposition. This review summarizes the cellular and molecular mechanisms governing the volume of white adipose tissue (WAT), and outlines the physiological signals that regulate these processes. Particular attention is given to the role of the gastric hormone, ghrelin, describing its actions in general and presenting detailed evidence of its role in regulating adipocyte biology. Combining this evidence with an analysis of the factors governing ghrelin secretion, leads to the hypothesis that during periods of food deprivation ghrelin acts as an energy deficit signal, defending the fat stored in responsive WAT against the forces of utilization. This scenario has clear implications for programmes of sustainable weight loss.